Halozyme cellulite treatment performs well in study

Halozyme's (HALO) HTI-501 significantly improved the appearance of cellulite on patients' skin in a Phase I/II trial, thereby meeting the main goal of the study.

Halozyme's effect was compared with a control vehicle and with the skin prior to treatment.

The effect was maintained at three and six months.

Share are +5.5% premarket. (PR)

From other sites
Comments (10)
  • Trickdog
    , contributor
    Comments (581) | Send Message
    Great news! And was not expected, while the next upcoming data this month is big and should also be good news. More good news coming in the next few months to include a few drug approvals, one in EU, Mabthera SC, and the Baxter drug in US. Halo has also been spoken of as a big M&A candidate for the year by several sources.
    25 Mar 2014, 09:09 AM Reply Like
  • 487371
    , contributor
    Comments (13) | Send Message
    Who are they kidding? A "treatment" for cellulite?
    Maybe HGH would work, but don't get sucked into this product except for pump & dump.
    Remember HEB?
    25 Mar 2014, 09:44 AM Reply Like
  • pwd9398
    , contributor
    Comments (94) | Send Message
    The p-values from their study are some of the strongest I have seen in a long time, I think it is safe to say that this VERY statistically significant finding is not a pump-and-dump. Also it does bode well for the rest of their pipeline, but I did not know they had other near-term catalysts coming up as trickdog suggests.


    (slightly) long $HALO via Jan 2015 calls
    25 Mar 2014, 10:04 AM Reply Like
  • fezziwig2008
    , contributor
    Comments (153) | Send Message
    Hylenex for Insulin pumps (1/2Million in the US- growing 38% over next 2 yrs)- phas FOUR Data ghas been promised by 3/31- EOQ. Halozyme has already filed with the FDA for a new label for this approved product's new target. One doesn't apply for new labels on bad data.
    25 Mar 2014, 05:54 PM Reply Like
  • Joe McCann
    , contributor
    Comments (268) | Send Message
    Strong data in an area that has no treatment options. Everything out there right now is nonsense and doesn't hold up 2 weeks - let alone 6 months.


    The other interesting drug in this space is Xiaflex from Auxilium. A big enough market for more than 1 product.


    If this drug works for 6 months - many women will be getting injections around April every spring to get ready for shorts and bathing suits all summer. Huge potential drug.


    (Long HALO)
    25 Mar 2014, 11:41 AM Reply Like
  • fezziwig2008
    , contributor
    Comments (153) | Send Message
    PFE dropped Xiaflex in England at the time they signed up w HALO on Enhanze- 6 target deal- maybe HTI-501 next.
    25 Mar 2014, 05:55 PM Reply Like
  • Joe McCann
    , contributor
    Comments (268) | Send Message
    Perhaps - The Xiaflex launch was a real dog for PFE though...AGN is the company that makes sense for a cellulite product hands down IMO.
    25 Mar 2014, 05:58 PM Reply Like
  • fezziwig2008
    , contributor
    Comments (153) | Send Message
    3 Steps to a Mint in HTI-501 profits


    1.Cellulite is a $10B Worldwide market.


    2.MD's are starving for fee for service procedures.


    3.Unlike Injecting Botox, with it's distal effect due to migration, HTI 501 is rapidly pH neutralized - so it cuts the cord in the dimple in which its injected- smoths it and becomes neutralized- like a bee that leaves its stinger. SO, MAny MD's of all specialties and none will inject- Family practitioners, OB GYNs, etc- A Mint for the right marketer- Allergan, Pfizer, or Valeant.
    25 Mar 2014, 06:01 PM Reply Like
  • KCConor
    , contributor
    Comments (5) | Send Message
    HYLENEX info from $HALO is due


    by end of month. Correct?
    26 Mar 2014, 10:03 PM Reply Like
  • Joe McCann
    , contributor
    Comments (268) | Send Message
    Yes "end of Q1" - I Keep track of all my catalysts on the company I'm building:




    From the catalyst record for HALO's trial I made a few weeks ago:


    "CONSISTENT 1 is a multicenter, randomized, Phase IV trial that includes approximately 400 subjects in 40 centers across the country. This study is designed to evaluate treatment differences in safety and key outcomes, with endpoints at 4 and 12 months measuring A1C, postprandial glucose and rates of hypoglycemia, among many other safety parameters. And while the primary analysis is at 4 months, this study will continue to monitor patients for up to 2 years." ~ Piper conference comments


    From Q1 2013 conference call about the trial:
    "the data suggests that an additional challenge comes from insulin absorption from the subcutaneous tissue, which is suboptimal for many patients and can lead to a challenging balance between hypo and hyperglycemia. Our goal is to see if Hylenex can deliver a more physiologic insulin profile for patients on pumps, which could help some people better manage their diabetes. This trial is designed to capture more real world results, taking into account the various challenges and variables this population faces. For example, some people with type 1 diabetes struggle to bring down their A1C. Others have challenges with the glucose excursions, while for some, the biggest challenge is hypoglycemia. Studying this broader population in a Phase IV setting will ensure clinicians understand how Hylenex works in all of these settings. Additionally, this study will help support the continued safety of exposure in the specific patient population when used across various insulins, pumps and infusion sets."
    27 Mar 2014, 01:20 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs